Potential COVID-19 treatment and vaccine combination shows success in cells
A possible treatment and vaccine combination for COVID-19 has shown positive results in pre-clinical studies using human cells.
List view / Grid view
A possible treatment and vaccine combination for COVID-19 has shown positive results in pre-clinical studies using human cells.
Five immune response biomarkers have been identified by researchers who say they can be used to classify which COVID-19 patients will survive the disease.
Researchers have found the small molecules Apilimod and Vacuolin-1 inhibited the PIKfyve kinase in cells, preventing infection from Zaire ebolavirus and SARS-CoV-2.
A new decoy receptor of ACE2 has been created which binds to and neutralises COVID-19 in live tissue cultures, preventing cells from becoming infected.
According to researchers, drugs that target envelope protein E on the SARS viral membrane could also be used to target a similar protein on COVID-19.
Research has shown T cells taken from patients with COVID-19 target the same three to eight immunodominant epitopes - most of which are not on the Spike protein.
A UK company has announced that their lung epithelium model can successfully be used to test potential treatments for COVID-19.
Researchers have found that using GRL-0617, an PLpro inhibitor, in cell cultures blocked SARS-CoV-2 production and supported the cell immune response.
Researchers say computational analyses suggest the bradykinin system may explain some of the symptoms of COVID-19, providing a drug target.
A study has demonstrated that the LY6E protein inhibits SARS-CoV-2 infection in human cell cultures, so a drug mimicking it could be a therapy for COVID-19.
According to new research, sulfated polysaccharides extracted from seaweed were more effective at inhibiting SARS-CoV-2 infection in mammalian cells than remdesivir.
A study of the SARS-CoV-2 nonstructural protein 1 (Nsp1) showed it can supress translation and inhibit anti-viral defence mechanisms, making it a potential target for drugs.
The newly identified hallmarks of critical COVID-19 indicate a combination of interferon supplementation and anti-inflammatory therapies could be effective in treating patients with severe COVID-19 symptoms.
Researchers report COVID-19 can cause a range of severe neurological symptoms, which may be the main presentation of COVID-19 in some patients.
The genomic research platform will initially be used to help fast-track COVID-19 drug research and development, before being leveraged against other diseases, such as cancer.